The reduction of uric acid levels and improvement of endothelial function also play a role in mitigating renal injury [159], highlighting the multifaceted mechanisms through which SGLT2 inhibitors exert their benefits in obesity-related CKD. The gene discussed is SLC5A2; the disease is chronic kidney disease.